IL287264A - Compounds and methods for the treatment of ocular disorders - Google Patents
Compounds and methods for the treatment of ocular disordersInfo
- Publication number
- IL287264A IL287264A IL287264A IL28726421A IL287264A IL 287264 A IL287264 A IL 287264A IL 287264 A IL287264 A IL 287264A IL 28726421 A IL28726421 A IL 28726421A IL 287264 A IL287264 A IL 287264A
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- treatment
- methods
- ocular disorders
- ocular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835963P | 2019-04-18 | 2019-04-18 | |
| PCT/IB2020/000288 WO2020212755A1 (en) | 2019-04-18 | 2020-04-16 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL287264A true IL287264A (en) | 2021-12-01 |
Family
ID=72837744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287264A IL287264A (en) | 2019-04-18 | 2021-10-14 | Compounds and methods for the treatment of ocular disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10875845B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3955926A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7700045B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220003555A (cg-RX-API-DMAC10.html) |
| CN (1) | CN114025759A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020259996B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3137583A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL287264A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020212755A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020212755A1 (en) * | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN116635032A (zh) * | 2020-10-21 | 2023-08-22 | 阿祖拉眼科有限公司 | 用于治疗眼部病症的化合物和方法 |
| EP4232458A4 (en) * | 2020-10-21 | 2024-10-02 | Azura Ophthalmics Ltd | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| WO2023067387A2 (en) * | 2021-10-20 | 2023-04-27 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of dermal and ocular disorders |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US7056893B2 (en) | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US20040005641A1 (en) | 2002-02-15 | 2004-01-08 | Michael Burnet | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| AU2004287875B2 (en) * | 2003-11-05 | 2011-06-02 | Bausch + Lomb Ireland Limited | Modulators of cellular adhesion |
| SI1881823T1 (sl) | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje bolezni oäśesa |
| DE102005062987A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP3632444A3 (en) * | 2008-04-15 | 2020-08-26 | SARcode Bioscience Inc. | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| EP2877465A4 (en) * | 2012-07-25 | 2016-05-11 | Sarcode Bioscience Inc | LFA-1 HEMMER AND POLYMORPH THEREOF |
| EP3827823A1 (en) * | 2012-12-19 | 2021-06-02 | Novartis AG | Lfa-1 inhibitor formulations |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| CA3020713A1 (en) * | 2016-04-19 | 2017-10-26 | Azura Ophthalmics Ltd. | Compositions for the treatment of hyperkeratosis disorders |
| US11420995B2 (en) | 2017-03-03 | 2022-08-23 | Synovo Gmbh | Anti-infective and anti-inflammatory compounds |
| CA3057569A1 (en) | 2017-03-29 | 2018-10-04 | Azura Ophthalmics Ltd. | Agents for increasing meibomian gland lipid secretion |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| AU2020259997B2 (en) | 2019-04-18 | 2025-08-07 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| WO2020212755A1 (en) | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CA3196145A1 (en) | 2020-10-21 | 2022-04-28 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
-
2020
- 2020-04-16 WO PCT/IB2020/000288 patent/WO2020212755A1/en not_active Ceased
- 2020-04-16 AU AU2020259996A patent/AU2020259996B2/en not_active Expired - Fee Related
- 2020-04-16 EP EP20791787.3A patent/EP3955926A4/en active Pending
- 2020-04-16 CA CA3137583A patent/CA3137583A1/en active Pending
- 2020-04-16 KR KR1020217037591A patent/KR20220003555A/ko not_active Ceased
- 2020-04-16 CN CN202080044807.9A patent/CN114025759A/zh active Pending
- 2020-04-16 JP JP2021559917A patent/JP7700045B2/ja active Active
- 2020-06-17 US US16/904,036 patent/US10875845B2/en active Active
- 2020-12-04 US US17/112,371 patent/US11634411B2/en active Active
-
2021
- 2021-10-14 IL IL287264A patent/IL287264A/en unknown
-
2023
- 2023-03-08 US US18/119,248 patent/US20230357207A1/en active Pending
-
2025
- 2025-11-07 US US19/382,548 patent/US20260234132A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220003555A (ko) | 2022-01-10 |
| EP3955926A4 (en) | 2022-11-30 |
| AU2020259996A1 (en) | 2021-11-25 |
| US20230357207A1 (en) | 2023-11-09 |
| JP2022530322A (ja) | 2022-06-29 |
| CA3137583A1 (en) | 2020-10-22 |
| US20260234132A1 (en) | 2026-08-13 |
| JP7700045B2 (ja) | 2025-06-30 |
| US11634411B2 (en) | 2023-04-25 |
| US20200331896A1 (en) | 2020-10-22 |
| US20210107899A1 (en) | 2021-04-15 |
| EP3955926A1 (en) | 2022-02-23 |
| AU2020259996B2 (en) | 2025-07-03 |
| CN114025759A (zh) | 2022-02-08 |
| US10875845B2 (en) | 2020-12-29 |
| WO2020212755A1 (en) | 2020-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287280A (en) | Compounds and methods for the treatment of ocular disorders | |
| IL288214A (en) | Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders | |
| IL286636A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS | |
| IL278178A (en) | Use of pilocarpine hydrochloride to treat eye disorder | |
| IL267818A (en) | Methods for treating neurological disorders | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| IL279634A (en) | Preparations and methods for the treatment and prevention of neurological disorders | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| SG11202100092QA (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS | |
| EP3661502A4 (en) | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES | |
| IL269400A (en) | Medicines and preparations for the treatment of eye disorders | |
| PT3603621T (pt) | Lipossomas para o tratamento de doenças oculares | |
| EP4010347A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PAIN AND ADDICTION DISORDERS | |
| EP3644966A4 (en) | TREATMENT AND DIAGNOSIS OF EYE SURFACE DISORDERS | |
| IL289221A (en) | Compounds for the treatment of vision disorders | |
| EP4232458A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES | |
| SG11202012473UA (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| IL288234A (en) | Compounds for the treatment of neuromuscular disorders | |
| IL317599A (en) | Device for treating eye disorders | |
| IL280588A (en) | Ophthalmic compositions and methods for treating eye problems and skin diseases | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| HK40074660A (en) | Methods for the treatment of apoc3-related diseases and disorders | |
| HK40084516A (en) | Compounds and methods for the treatment of eye disorders | |
| AU2020901856A0 (en) | Compounds and Methods for the Treatment of Eye Disorders | |
| AU2020901858A0 (en) | Compounds and Methods for the Treatment of Eye Disorders |